Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Staudinger, Heribert" or (type exact bookEditor and editor="Staudinger, Heribert")

Add to list
- Journal Article
- A1
- open access
Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps

Joaquim Mullol, Claus Bachert (UGent) , Nikhil Amin, Martin Desrosiers, Peter W Hellings, Joseph K Han, Roger Jankowski, Jan Vodicka, Philippe Gevaert (UGent) , Nadia Daizadeh, et al.

(2022) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE. 10(4). p.1086-1095.e5
Add to list
- Journal Article
- A1
- open access
Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma

Tanya M. Laidlaw, Claus Bachert (UGent) , Nikhil Amin, Martin Desrosiers, Peter Hellings (UGent) , Joaquim Mullol, Jorge F. Maspero, Philippe Gevaert (UGent) , Mei Zhang, Xuezhou Mao, et al.

(2021) ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY. 126(5). p.584-592.e1
Add to list
- Miscellaneous
3TR : a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD

Celeste Porsbjerg, Anke H. Maitland-van der Zee, Guy Brusselle (UGent) , Giorgio Walter Canonica, Alvar Agusti, Rosa Faner, Claus F. Vogelmeier, Martijn Nawijn, Maarten van den Berge, Franca Rusconi, et al.

(2021) EUROPEAN RESPIRATORY JOURNAL. 58(4).
Add to list
Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP

Claus Bachert (UGent) , S James Zinreich, Peter Hellings (UGent) , Joaquim Mullol, Daniel L Hamilos, Philippe Gevaert (UGent) , Robert M Naclerio, Nikhil Amin, Vikay N Joish, Chunpeng Fan, et al.

(2020) RHINOLOGY. 58(1). p.10-17
Add to list
Dupilumab improves health‐related quality of life in patients with chronic rhinosinusitis with nasal polyposis

Claus Bachert (UGent) , Peter Hellings (UGent) , Joaquim Mullol, Daniel L Hamilos, Philippe Gevaert (UGent) , Robert M Naclerio, Vijay N Joish, Jingdong Chao, Leda P Mannent, Nikhil Amin, et al.

(2020) ALLERGY. 75(1). p.148-157
Add to list
- Conference Paper
- C3
Dupilumab consistently improves rhinoconjunctivitis-specific health-related quality of life in patients with uncontrolled, moderate-to-severe asthma and comorbid allergic rhinitis : results from the phase 3 LIBERTY ASTHMA QUEST study

Jean Bousquet, Jorge F Maspero, Bradley E Chipps, Jonathan Corren, J Mark FitzGerald, Zhen Chen, Yufang Lu, Paul Rowe, Heribert Staudinger, Marcella Ruddy, et al.

(2019) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. In Journal of Allergy and Clinical Immunology 143(2). p.AB101-AB101
Add to list
- Journal Article
- A1
- open access
Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma

Claus Bachert (UGent) , Peter Hellings (UGent) , Joaquim Mullol, Robert M Naclerio, Jingdong Chao, Nikhil Amin, Annette Grabher, Brian N Swanson, Jennifer D Hamilton, Sophie Guillonneau, et al.

(2019) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE. 7(7). p.2447-2449
Add to list
Efficacy and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps : results from the randomized phase 3 sinus-24 study

Joseph K Han, Claus Bachert (UGent) , Martin Desrosiers, Tanya M Laidlaw, Claire Hopkins, Wytske J Fokkens, Pierluigi Paggiaro, Seong Ho Cho, Heidi Olze, Leon S Greos, et al.

(2019) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 143(2, suppl.). p.AB422-AB422
Add to list
- Conference Paper
- C3
- open access
A randomized phase 3 study, SINUS-52, evaluating the efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps

Claus Bachert (UGent) , Martin Desrosiers, Joaquim Mullol, Peter Hellings (UGent) , Anders Cervin, Lawrence Sher, John V Bosso, Stella E Lee, Jorge F Maspero, Shigeharu Fujieda, et al.

(2019) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 143(2, suppl.). p.AB433-AB433
Add to list
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52) : results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

Claus Bachert (UGent) , Joseph K Han, Martin Desrosiers, Peter W Hellings, Nikhil Amin, Stella E Lee, Joaquim Mullol, Leon S Greos, John V Bosso, Tanya M Laidlaw, et al.

(2019) LANCET. 394(10209). p.1638-1650

Academic Bibliography

Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps

Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma

3TR : a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD

Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP

Dupilumab improves health‐related quality of life in patients with chronic rhinosinusitis with nasal polyposis

Dupilumab consistently improves rhinoconjunctivitis-specific health-related quality of life in patients with uncontrolled, moderate-to-severe asthma and comorbid allergic rhinitis : results from the phase 3 LIBERTY ASTHMA QUEST study

Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma

Efficacy and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps : results from the randomized phase 3 sinus-24 study

A randomized phase 3 study, SINUS-52, evaluating the efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52) : results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

Contents

Support

Contact